Annexure V

Contents Of The Research Proposals

INSTITUTIONAL ETHICS COMMITTEE

HM PATEL CENTER FOR MEDICAL CARE AND EDUCATION, KARAMSAD

1. Title Page:

a) Full title of the clinical study
b) Protocol /Study number and protocol version number with date
c) The IND name/number of the investigational drug
d) Complete name and address of the Sponsor and contract research organization, if any
e) List of the investigators who are conducting the study, their respective institutional affiliations and site locations
f) Name(s) of clinical laboratories and other departments and /or facilities participating in the study

2. Table of contents:

A complete Table of Content including a list of all Appendices.

1. Background and Introduction

(a) Pre-clinical experience
(b) Clinical experience

Previous clinical work with the new drug should be reviewed here and a description of how the current protocol extends data should be provided. If this is an entirely new indication, how this drug was considered for this should e discussed. Relevant information regarding pharmacological, toxicological and other biological properties of the drug/ biologic/ medical device, and previous efficacy and safety experience should be described.

2. Study Rationale

This section should describe a brief summary of the background information relevant to the study design and protocol methodology. The reason for performing this study in the particular population included by the protocol should be provided.

3. Study objective(s) (primary as well as secondary)and their logical relation to the study design

4. Study design:

a) *Overview of the Study Design*: Including a description of the type of study (i.e. double -blind, multicentre, placebo controlled, etc.), a detail of the specific treatment groups and number of the study Subjects in each group and investigative site, Subject number assignment, and the type, sequence and duration of study periods .

b) *Flow chart of the study*
c) *A brief description of the methods and procedures to be used during the study.*

d) *Discussion of the study Design: This discussion details the rational for the design chosen for this study*

5. **Study population:** The number of subjects required to be enrolled in the study at the investigative site and by all sites along with a brief description of the nature of the subject population required is also mentioned.

6. **Subject eligibility:**
   (a) Inclusion Criteria
   (b) Exclusion Criteria

7. **Study assessments:** Plan, procedures and methods to be described in detail

8. **Study conduct stating the types of study activities that would be included in this section would be:**

   a) Medical history, type of physical examination, blood or urine testing, electrocardiogram (ECG), diagnostic testing such as pulmonary function tests symptom measurement, dispensation and retrieval of medication, subject cohort assignment, adverse event review, etc.
   b) Each visit should be described separately as Visit 1, Visit 2, etc.
   c) *Discontinued Subjects:* Describe the circumstances for subject withdrawal, dropouts, or other reasons for discontinuation of Subjects. State how dropouts would be managed and if they would be replaced.
   d) Describe the method of handling of protocol waivers, if any. The person(s) who approves all such waivers should be identified and the criteria used for specific waivers should be provided.
   e) Describe how protocol violations will be treated, including conditions where the study will be terminated for non -compliance with the protocol.

9. **Study treatment:**
   a) Dosing *schedule (dose, frequency, and duration of the experimental treatment :)* Describe the administration of placebos and /or dummy medication if they are part of the treatment plan. If applicable, concomitant drug(s), their doses, frequency, and duration of concomitant treatment should be stated.

   b) Study drug supplies and administration: A statement about who is going to provide the study medication and that the investigational drug formulation has been manufactured following all regulations. Details of the product stability, storage requirement and dispensing requirement should be provided.

c) *Dose modification for study drug toxicity*: Rules for changing the dose or stopping the study drug should be provided.

d) Possible drug interactions.

e) *Concomitant therapy:* The drug that are permitted during the study and the condition under which they may be used are detailed here. Describe the drug that a Subject is not allowed to use during parts of or the entire study. If any washout periods for prohibited medications are needed prior to enrolment, these should be described here.

f) *Blinding procedures:* A detailed description of the blinding procedure if the study employs a blind on the Investigator and /or the Subject.

g) *Unblinding procedures*: If the study is blinded, the circumstances in which unblinding may be done and the mechanism to be used for unblinding should be given.

10. Adverse events [see Appendix XI, Schedule Y]: Description of expected adverse events should be given.
Procedures used to evaluate an adverse event should be described.

11. Ethical considerations: Give the summary of:
a) Risk /benefit assessment
b) Ethics Committee review and communications
c) Informed consent process
d) Statement of Subject confidentiality including ownership of data coding procedures

12. Study monitoring and Supervision:
a) A description of study monitoring policies and procedures should be provided along with the proposed frequency of the site monitoring visits, and who is expected to perform monitoring.
b) Case Record Form (CRF) completion requirement, including who gets which copies of the forms and any specifics required in filling out the forms CRF correction requirements, including who is authorized to make corrections on the CRF and how queries about study data are handled and how errors, if any, are to be corrected should be stated.
c) Investigator study files, including what needs to be stored following study completion should be described.

13. Investigational Product management:
a) Give Investigational product description and packaging (stating all Ingredients and the formulation of the investigational drug and nay placebo used in the study)

b) The precise dosing required during the study.
c) Method of the packaging, labelling and blinding of the study substances.
d) Methods of assigning treatments to Subjects and the Subject identification code numbering system.
e) Storage condition for the study substances.
f) Investigational product accountability: Describe instructions for the receipt, storage, dispensation, and return of the investigational product to ensure a complete accounting of all investigational products received, dispensed, and returned/ destroyed.
g) Describe policy and procedure for handling unused investigational products.

14. Data analysis:

a) Provide details of the statistical approach to be followed including sample size, how the sample size was determined, including assumptions made in making this determination, efficacy endpoints (primary as well as secondary) and safety endpoints.
b) *Statistical analysis:* Give complete details of how the results will be analysed and reported along with the description of statistical tests to be used to analyse the primary and secondary endpoints defined above. Describe the level of significance, statistical tests to be used, and the methods used for missing data; method of evaluation of the data for treatment failures, non-compliance, and subject withdrawals; rationale and condition for nay interim analysis if planned.
c) Describe statistical considerations for Pharmacokinetic (PK) analysis, if applicable.

15. Undertaking by Investigator [as per Appendix VII, Schedule Y]:

16. Appendices: Provide a study synopsis, copies of the informed consent document (patient information sheet, informed consent form etc.); CRF and other data collection forms; a summary of relevant pre-clinical safety information and any other document referenced in the clinical protocol.